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OBJECTIVES The aim of this trial was to compare cutting balloon angioplasty (CBA) with conventional
balloon angioplasty (i.e., percutaneous transluminal coronary angioplasty [PTCA]) for the
treatment of patients with coronary in-stent restenosis (ISR).
BACKGROUND Retrospective studies suggest CBA might be superior to conventional PTCA in the treatment
of ISR.
METHODS The Restenosis Cutting Balloon Evaluation Trial (RESCUT) is a multicenter, randomized,
prospective European trial including 428 patients with all types of ISR (e.g., focal, multifocal,
diffuse, proliferative).
RESULTS In both groups, the majority of ISR lesions were shorter than 20 mm. The length of restenotic
stents was similar (CBA: 18.6  9.7 mm; PTCA: 18.3  8.7 mm). The number of balloons
used to treat ISR was lower in the CBA group: only one balloon was used in 82.3% of CBA
cases, compared with 75% of PTCA procedures (p  0.03). Balloon slippage was less
frequent in the CBA group (CBA 6.5%, PTCA 25%; p  0.01). There was a trend toward
a lower need for additional stenting in the CBA group (CBA 3.9%, PTCA 8.0%; p  0.07).
At seven-month angiographic follow-up, the binary restenosis rate was not different between
the groups (CBA 29.8%, PTCA 31.4%; p  0.82), with a similar pattern of recurrent
restenosis. Clinical events at seven months were also similar.
CONCLUSIONS Cutting balloon angioplasty did not reduce recurrent ISR and major adverse cardiac events,
as compared with conventional PTCA. However, CBA was associated with some procedural
advantages, such as use of fewer balloons, less requirement for additional stenting, and a lower
incidence of balloon slippage. (J Am Coll Cardiol 2004;43:943–9) © 2004 by the American
College of Cardiology Foundationa
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fith the rapid explosion in-stent use, in-stent restenosis
ISR) has become a significant clinical problem (1). Redi-
ation using a conventional percutaneous transluminal cor-
nary angioplasty (PTCA) balloon remains the most com-
only used approach to treat ISR (2–5). However, the
ecurrence rate remains high, especially in the subgroup of
atients with diffuse and/or severe ISR (1,3,5–8). Intravas-
ular ultrasound (IVUS) studies have shown that ISR is due
o neointimal hyperplasia (9). Thus, debulking techniques
hat use different devices have been studied for its treatment
1,10,11). However, all these atheroablative technologies
emain difficult to handle, and they are costly. In addition,
From the *Columbus Hospital, Milan, Italy; †Mu¨ller Hospital, Munich, Germany;
San Raffaele Hospital, Milan, Italy; §Ospedale Maggiore della Carita`, Novara, Italy;
Clinica Montevergine, Mercogliano (AV), Italy; ¶Ospedale Civile, Mirano, Italy;
Casa di Cura Villa Maria Eleonora, Palermo, Italy; **Klinikum Innenstadt Abteilung
ardiologie, Munich, Germany; ††Hospital Santa Creu I Sant Pau, Barcelona, Spain;
‡Ospedale San Martino, Genova, Italy; §§Institut Cardiovasculaire Paris Sud,
assy, France;  Casa di Cura Villa Maria Cecilia, Cotignola (RA), Italy; ¶¶Kar-
iologische Klinik Andreas-Gru¨nzig-Haus, Hamburg, Germany; and ##Policlinico,
ari, Italy. This study was supported by Boston Scientific Europe Corporation, Paris,
rance.
Manuscript received July 23, 2003; revised manuscript received September 5, 2003,wccepted September 9, 2003.recent randomized, multicenter study (12) has failed to
emonstrate the superiority of rotational atherectomy over
onventional PTCA in the treatment of ISR. Another
evice proposed for treatment of ISR is the cutting balloon
Boston Scientific Corp., InterVentional Technologies Eu-
ope Ltd., Letterkerry, Ireland) (13), a special balloon
atheter with three or four microsurgical blades bonded
ongitudinally to its surface, suitable to incise and facilitate
edistribution of the ISR plaque. Retrospective studies
14,15) suggest that cutting balloon angioplasty (CBA)
ight be superior to conventional PTCA in the treatment
f ISR. The aim of this randomized study was to compare
BA with conventional PTCA.
ETHODS
tudy design and objectives. The Restenosis Cutting
alloon Evaluation Trial (RESCUT) was a prospective,
andomized, multicenter trial performed at 23 centers in
urope (Appendix) to evaluate the immediate and seven-
onth results of CBA compared with conventional PTCA
or the treatment of all types of ISR. The primary end point
as angiographic restenosis (50% diameter reduction) of
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Cutting Balloon Versus PTCA for ISR March 17, 2004:943–9he target lesion, as assessed by quantitative coronary an-
iography (QCA) at seven-month follow-up in the two
reatment arms. Secondary end points were the occurrence
f major adverse clinical events (MACE) at 30 days and
even-month follow-up in the two treatment arms, the need
or additional stent implantation in each arm, and the
attern of restenosis recurrence.
tudy population. Patients fulfilled the following inclusion
riteria: 1) angina and/or objective evidence of target vessel-
elated ischemia by a functional study; 2) target lesions
ocated in native coronary arteries with single or multiple
maximum of three) ISR and with an angiographic percent
iameter stenosis (%DS) between 51% and 99% by visual
ssessment; and 3) lesions that could be focal (10 mm),
ultifocal, diffuse (10 mm), or proliferative (extending
utside the stent margins), with a total lesion length 25
m. Patients were excluded for the following reasons: 1)
nown allergy to the study medication (e.g., heparin, ticlo-
idine, clopidogrel, aspirin); 2) recent myocardial infarction
72 h), defined as a serum level 2  the upper limit of
ormal of creatine kinase (CK) and elevated MB fraction; 3)
oncomitant PTCA in another vessel during the same
rocedure or within 30 days; 4) additional brachytherapy
fter the randomized mechanical treatment of ISR by CBA
r conventional PTCA; 5) the lesion was located in an
nternal mammary artery, saphenous vein bypass graft, or
nprotected left main coronary artery; and 6) ISR was in a
ifurcated stent. A status of recurrent intrastent restenosis
e.g., second time, third time, and so on) was not considered
n exclusion criterion for entry into the study.
nterventional procedures. THE CBA ARM. The cutting
alloon device (Boston Scientific Corp.) was a 10- to
5-mm-long cutting balloon selected with the same or
.25- to 0.5-mm larger diameter than the vessel size. The
utting balloon was positioned at the lesion site (using
redilation with a small conventional balloon in case of
nsuccessful passage) and inflated to the recommended
aximal pressure of 8 to 12 atm.
HE PTCA ARM. The PTCA procedure was done using
oncompliant or semicompliant balloons that matched the
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CBA  cutting balloon angioplasty
CK  creatine kinase
%DS  percent diameter stenosis
ISR  in-stent restenosis
IVUS  intravascular ultrasound
MACE  major adverse cardiac events
MLD  minimum lumen diameter
PTCA  percutaneous transluminal coronary
angioplasty
QCA  quantitative coronary angiography
RESCUT  Restenosis Cutting Balloon Evaluation Trialize of the final balloon used at the time of stent implanta- Iion. The balloon was inflated at high pressure (10 to 12
tm), with the goal of achieving near 0% residual stenosis.
OTH ARMS. At least three separate, slow balloon inflations
ere recommended at the lesion site, preferably moving
istal to proximal, to fully cover the lesion area to be treated.
he occurrence of slippage of the balloon, defined as a
orward or backward movement of the balloon of at least 3
m during its inflation at the lesion site, and dissections
utside of the stent after deflation of the balloon were
ecorded. In case the balloon did not expand, the lesion
ould be treated with other devices, such as rotational
therectomy (Rotablator, Boston Scientific Corp., Cork,
reland), directional atherectomy, laser atherectomy, or a
ifferent balloon. If the angiographic result was not accept-
ble with residual stenosis 30%, the implantation of an
dditional stent was recommended. However, the investi-
ators were free to select the more appropriate device for the
esions in which balloon treatment failed.
oronary angiography. Three coronary angiograms were
erformed in each patient: one before and one immediately
fter the procedure and one after seven months from the
nitial procedure. At least two orthogonal projections of the
oronary segment scheduled for coronary intervention were
lmed before the intervention. The same projections were
epeated after the intervention and at follow-up angiogra-
hy. Each angiogram was preceded by intracoronary injec-
ion of nitrates (100 to 200 g nitroglycerin or 1 to 3 mg
sosorbide dinitrate). The angiographic findings of dissec-
ion were recorded and analyzed.
uantitative coronary angiography. Reference diameter,
inimum lumen diameter (MLD), %DS, and lesion length
ere measured for each lesion from the single view showing
he most severe degree of stenosis by the use of a computer-
ssisted automated edge-detection algorithm (QCA-CMS
ersion 4.0, MEDIS, Leiden, the Netherlands). Inter- and
ntra-observer variabilities have been reported to range from
.07 to 0.10 mm for MLD and 2.7% to 5.1% for %DS, even
hen using the most precise angiographic systems (16–18).
cute lumen gain was defined as the MLD immediately after
he procedure minus the MLD before the procedure. Late
umen loss was defined as the MLD after the procedure
inus the MLD at follow-up. The late loss index was
efined as the late lumen loss divided by the acute lumen
ain. Restenosis was defined as 50% DS inside the stent or
ithin 5 mm from the stent edges, presenting at least eight
eeks after the initial stent implantation or after successful
reatment of ISR. In addition, ISR was defined as focal
10 mm in length) or diffuse (10 mm in length).
oncomitant medications. All patients received 100 to
25 mg aspirin plus 250 mg ticlopidine twice daily, or 75
g/day clopidogrel before the procedure. Intraprocedural
eparin was given as an intravenous bolus of 70 to 100 U/kg
fter sheath insertion and then repeated as needed to keep
he activated clotting time 200 to 250 s. Glycoprotein
Ib/IIIa inhibitors were given at the operator’s discretion
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March 17, 2004:943–9 Cutting Balloon Versus PTCA for ISRnly in selected patients. After the procedure, heparin was
topped and the sheath removed. All patients at discharge
eceived 100 to 325 mg/day aspirin indefinitely plus 250 mg
iclopidine twice daily, or 75 mg/day clopidogrel for 1 week.
he further use of ticlopidine/clopidogrel for one month
as recommended only in patients who required the im-
lantation of additional stents.
linical follow-up. In-hospital, 30-day, and cumulative
-month MACE were defined as death, any myocardial
nfarction, and/or repeat revascularization (coronary artery
ypass graft surgery [CABG]/repeat PTCA). A diagnosis
f Q-wave myocardial infarction was made when there was
ocumentation of new pathologic Q waves (0.04 s) on the
lectrocardiogram in conjunction with elevation of total CK
ore than twice the normal value, with a concomitant
levation of the CK-MB. A diagnosis of non–Q-wave
yocardial infarction was made when an elevation of total
K to greater than twice the upper limit of normal value,
ith a concomitant elevation of CK-MB, was documented
ithout development of new pathologic Q waves. Twelve-
ead electrocardiograms were recorded before and immedi-
tely after the procedure and at hospital discharge, as well as
uring and after episodes of chest pain. Total CK and
K-MB levels were routinely obtained before and after the
rocedure and repeated after 6 and 12 h.
tatistical analysis. Based on retrospectively collected data
15), a restenosis rate of approximately 42% could be
xpected after treatment of intrastent restenosis using a
onventional balloon versus 27% using a cutting balloon.
ccepting these values, we estimated a sample size of about
20 patients (210 in each arm) to establish a statistically
ignificant difference between the two strategies, with an
lpha error of 0.05, a beta error of 0.20, and a two-sided
est. A drop-out rate of 20% was also considered. The
hi-square test was performed to test for homogeneity of
istribution of categorical data, reported as m  n contin-
ency tables; 2  2 contingency tables were analyzed
ccording to the Fisher exact test. Analysis of variance was
erformed for continuous data. Results are expressed as the
ean value  SD. The association between binary resteno-
is and the potential predictors was assessed via logistic
egression methods. Variables with biologic remarkable
redictivity (reference vessel diameter before procedure,
LD after procedure, diabetes, unstable angina, previous
estenosis of target lesion, time to last stent implantation)
nd parameters that were statistically significant on
nivariate analysis (lesion length, number of balloons
sed, type of lesion) were included in the multivariate
nalysis. A stepwise selection method according to the
aximum likelihood ratio was used to define the predic-
ors of the logistic model. The results were presented as
he odds ratio with 95% confidence interval for each
ariable. A value p  0.05 was considered statistically
ignificant. TESULTS
atient population and baseline lesion characteristics. A
otal of 428 patients were randomly assigned to CBA (n 
14 [229 lesions]) or PTCA (n  214 [237 lesions]).
aseline demographics and clinical characteristics (Table 1)
ere similar in both arms, except for previous CABG (CBA
2% vs. PTCA 6%; p  0.05). There were no significant
ifferences in baseline stent and lesion characteristics (Table
), except for a higher rate of multifocal, diffuse, or
roliferative lesions in the PTCA group. The majority of
SR was first ISR (CBA 84.6%, PTCA 81.5%; p  0.06)
nd 20 mm in length (CBA 86.7%, PTCA 83.6%; p 
.44).
rocedural characteristics. Procedural characteristics are
resented in Table 3. Failure to cross the lesion using the
utting balloon, known to have a worse profile than tradi-
ional balloons, was higher (CBA 5.2%, PTCA 0%; p 
.01). The procedural time was not different between the
wo devices.
The number of balloons used was significantly lower in
he CBA arm (patients treated with CBA required the use
f only one balloon in 82.3% of cases vs. 75.4% of PTCA
rocedures, p  0.03). Balloon slippage was less frequent in
he CBA group (CBA 6.5% vs. PTCA 25%; p  0.01).
oreover, the cutting balloon was shorter (due to its shorter
ength; available lengths of 10 or 15 mm), slightly larger,
nd inflated at a lower maximal inflation pressure (due to its
ower burst pressure; the manufacturer recommends 8 to 10
tm), compared with the longer (usually 20-mm long) and
igh-pressure conventional PTCA balloons (the manufac-
urers commonly recommend 14 to 18 atm). Finally, there
as a trend toward a lower need for additional stenting in
he CBA group (CBA 3.9% vs. PTCA 8.0%; p  0.07),
ainly due to a lower frequency of residual stenosis 30%
nd type D to F dissections in the CBA arm.
linical events and angiographic results. As shown in
able 1. Demographics and Baseline Characteristics
CBA
(n  214)
PTCA
(n  214) p Value
ge (yrs) 61.7  10.6 61.4  9.6 0.78
ale gender 171 (80%) 169 (79%) 0.90
nstable angina 54 (25%) 46 (21%) 0.84
iabetes 51 (24%) 58 (27%) 0.44
levated cholesterol 151 (71%) 155 (72%) 0.81
ypertension 137 (64%) 147 (69%) 0.39
urrent smoking 24 (11%) 30 (14%) 0.46
amily history of CAD 67 (31%) 79 (37%) 0.26
revious PTCA* 29 (14%) 19 (9%) 0.18
revious MI 111 (52%) 104 (49%) 0.56
revious CABG 26 (12%) 13 (6%) 0.05
jection fraction (%) 56.7  11.8 57.1  10.8 0.78
Previous conventional percutaneous transluminal coronary angioplasty (PTCA)
efore stent implantation in the target lesion with actual in-stent restenosis. Data are
resented as the mean value  SD or number (%) of patients.
CAD  coronary artery disease; CBA  cutting balloon angioplasty; CABG 
oronary artery bypass graft; MI  myocardial infarction.able 4, there were no differences between the two arms in
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Cutting Balloon Versus PTCA for ISR March 17, 2004:943–9linical events during the hospital stay and at 30-day
ollow-up since hospital discharge and in cumulative
ACE at 7-month follow-up.
Table 5 summarizes the QCA results. There were no
ifferences in MLD before and after the procedure and at
even-month follow-up angiography, which was conducted
n 82% of the patients in both arms (CBA: n 188; PTCA:
 194). The cumulative distribution curves of MLD are
resented in Figure 1. There were no significant differences
etween the two arms in %DS, late loss, loss index, and
ngiographic binary restenosis (CBA 29.8%, PTCA 31.4%;
 0.82), with a similar pattern of restenosis recurrence.
Table 6 shows the predictors of restenosis recurrence that
ere analyzed. On multivariate logistic regression analysis, a
onger baseline lesion length measured by QCA, a shorter o
T
N
M
M
F
N
B
B
A
D
P
F
D
QCA  quantitative coronary angioplasty; other abbreviationsime passed since implantation of a currently restenotic
arget stent, a higher number of balloons used, the presence
f unstable angina, and previous restenosis of the target
esion turned out to be independent predictors of restenosis
ecurrence.
ISCUSSION
n contrast to previous reports (14,15,19), in this large,
ulticenter, randomized study comparing CBA with con-
entional PTCA for the treatment of ISR, there were no
ignificant differences between the two approaches regard-
ng the study end points of recurrent angiographic binary
estenosis at seven-month follow-up, the occurrence of
ACE at 30 days and 7-month follow-up, and the patternable 2. Baseline Stent and Lesion Characteristics
CBA
(n  229)
PTCA
(n  237) p Value
revious implanted stents
Slotted tubular stents 81.3% 86.5% 0.18
Implantation interval (months) 10.1  12.4 8.71  11.9 0.22
Stent length (mm) 18.6  9.7 18.3  8.7 0.73
First in-stent restenosis 84.6% 81.5% 0.06
ype of stent restenosis 0.01
Focal (10 mm in length) 100 (51%) 74 (38%)
Multifocal/diffuse/proliferative 96 (49%) 120 (62%)
esion length 0.47
20 mm 170 (87%) 163 (84%)
20 mm 26 (13%) 31 (16%)
arget vessel 0.60
LAD 43% 46%
LCx 20% 22%
RCA 37% 32%
ata are presented as the percentage of patients, mean value  SD, or number (%) of patients.
LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery; RCA  right coronary artery; otherf restenosis recurrence.able 3. Procedural Characteristics
CBA
(n  229)
PTCA
(n  237) p Value
o. of balloons used 0.03
1 82.3% 75.4%
2 16.0% 19.2%
3 1.8% 5.4%
aximal balloon size (mm) 3.18  0.47 3.07  0.48 0.01
aximal inflation pressure (atm) 9.9  2.6 12.6  3.9 0.01
inal balloon length (mm) 11.3  3.2 18.3  4.6 0.01
o. of balloon inflations per lesion 2.83  1.7 2.75  2.3 0.65
alloon slippage 6.5% 25.1% 0.01
alloon-to-artery ratio (QCA) 1.27  0.20 1.25  0.20 0.27
dditional stent implantation 9 (3.9%) 19 (8.0%) 0.07
For residual stenosis 30% 2 (0.9%) 7 (2.9%)
For ischemia and dissection type C 2 (0.9%) 2 (0.9%)
For dissection type D, E, and F 5 (2.1%) 10 (4.2%)
issection post-procedure 4.8% 6.8% 0.48
rocedural time 97  85 89  75 0.28
ailure to cross the lesion 12 (5.2%) 0 0.01
ata are presented as the percentage of patients, mean value  SD, or number (%) of patients.
as in Table 1.
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March 17, 2004:943–9 Cutting Balloon Versus PTCA for ISRheoretical advantages of CBA over conventional
TCA for treatment of ISR. Previous IVUS studies
uggested a difference in the mechanisms of lumen enlarge-
ent after CBA and conventional PTCA. Mehran et al.
20) demonstrated by IVUS that the mechanism of conven-
ional PTCA for the treatment of ISR is a combination of
dditional stent expansion and tissue extrusion out of the
tent: of the total lumen enlargement, 56% is attributable to
dditional stent expansion, whereas 44% is the result of an
pparent decrease (displacement) in neointimal tissue. In
Table 4. In and Out of Hospital to Seven-Mo
per Patient
During hospital stay
Death
MI
CABG
Bleeding or vascular complications
After 30 days since hospital discharge
Death
MI
CABG
Repeat PCI
Bleeding or vascular complications
Subacute occlusion
Cumulative (in and out of hospital) MACE at 7 mo
Death
MI
TLR (repeat PCI and CABG)
Total patients with MACE
*Death, MI, CABG, and repeat PCI, TLR. †Patients with
severe MACE. ‡p values are calculated according to the Fis
CABG  coronary artery bypass graft surgery; MACE 
percutaneous coronary intervention; TLR  target lesion re
Table 5. Results of Quantitative Coronary Ang
CB
(n 
Reference vessel diameter (mm) 2.58 
MLD (mm)
Before treatment 0.83 
After treatment 2.17 
Acute gain 1.36 
7-month follow-up 188 (
MLD (mm) 1.61 
Late loss (mm) 0.56 
Loss index 0.43 
%DS
Before treatment 68 
After treatment 21 
7-month follow-up 188 (
%DS 39 
Lesion length
Before treatment (mm) 14.0 
Follow-up (mm) 10.8 
Restenosis (50% DS) 56 (
Pattern of restenosis recurrence
Focal (length 10 mm) 12 (
Diffuse (length 10 mm) 41 (
Data are presented as the mean value  SD or number (%)
%DS  percent diameter stenosis; MLD  minimal lumen diddition, a significant tissue re-intrusion shortly after
atheter-based treatment of ISR has been reported, which
esults in early lumen loss (21).
Our hypothesis was that CBA could have a potential
dvantage over conventional PTCA for the treatment of
SR because it could lead to less remaining tissue inside the
tent. This hypothesis was based on a previous observational
tudy (19) that demonstrated a greater capacity of CBA to
xtrude fibrous residual neointimal plaque out of the stent
truts, compared with conventional PTCA. The micro-
ollow-Up Major Adverse Cardiac Events*
CBA
(n  214)
PTCA
(n  214) p Value
0 0
1 (0.5%) 2 (0.9%) 0.99
0 0
4 (1.8%) 1 (0.5%) 0.37
0 0
1 (0.5%) 0 0.99
0 0
1 (0.5%) 1 (0.5%) 1
1 (0.5%) 0 0.99
0 0
3 (1.4%) 2 (0.9%) 0.99
3 (1.4%) 3 (1.4%) 1
29 (13.5%) 28 (13.1%) 0.99
35 (16.4%) 33 (15.4%) 0.79
than one MACE were counted only one time for the most
act test. Data are presented as the number (%) of patients.
adverse cardiac events; MI  myocardial infarction; PCI 
rization; other abbreviations as in Table 1.
aphy
PTCA
(n  237) p Value
2.53  0.45 0.23
0.84  0.32 0.87
2.16  0.43 0.78
1.32  0.50 0.39
194 (82%)
1.55  0.62 0.23
0.62  0.61 0.42
0.45  0.47 0.72
67  11 0.54
21  10 0.60
) 194 (81.9%)
40  21 0.31
13.4  6.4 0.39
11.3  7.5 0.46
) 61 (31.4%) 0.82
12 (21%) 0.26
44 (79%) 0.55
ients.nth F
nths†
more
her ex
majoriogr
A
229)
0.47
0.33
0.45
0.50
82%)
0.65
0.65
0.79
12
11
82.1%
22
7.9
6.6
29.8%
23%)
77%)
of pat
ameter; other abbreviations as in Table 1.
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Cutting Balloon Versus PTCA for ISR March 17, 2004:943–9lades of the cutting balloon are able to surgically incise the
estenotic plaques up to the metallic stent cage, and these
ncisions could facilitate the maximum extrusion of the
eointimal plaque, separated into three or four quadrants.
his hypothesis was confirmed by a recent IVUS study (14)
hat showed a larger lumen area acute gain after CBA (2.5
0.8 mm2) than after conventional PTCA (1.8  1.0
m2), which translated in a lower restenosis rate at 5.4-
onth follow-up (CBA 24%, PTCA 59%). Cutting balloon
ngioplasty also has a practical advantage over conventional
TCA for the treatment of ISR: conventional PTCA
alloons, especially short balloons, when positioned within
estenotic lesions, tend to move forward or backward during
nflation into larger segments with lower resistance, because
igure 1. Measurements by quantitative coronary angiography (QCA).
umulative distribution curves of minimum lumen diameter (MLD). CB
cutting balloon.
able 6. Predictors of Angiographic Binary Restenosis Recurrenc
Variables
Univa
OR (95% C
reatment (random) 0.984 (0.581–1.
linical
Gender 0.842 (0.440–1.
Diabetes 0.790 (0.440–1.
Unstable angina 0.583 (0.319–1.
Previous CABG 1.340 (0.473–3.
Previous restenosis of target lesion 0.486 (0.210–1.
Time to last stent implantation 1.030 (0.992–1.
ngiographic
Segment treated (LAD; other) 1.100 (0.650–1.
Baseline lesion length 0.940 (0.906–0.
Lesion length (20; 20) 1.660 (0.857–3.
Reference vessel diameter before procedure 1.030 (0.572–1.
MLD after procedure 1.390 (0.738–2.
Length of balloon 0.986 (0.939–1.
Type of lesion (focal, diffuse) 0.594 (0.345–1.
rocedural
Number of balloons used (1 vs. 1) 0.410 (0.220–0.
Maximum balloon size 0.921 (0.502–1.
Maximum inflation pressure 0.973 (0.897–1.
Diameter of final balloon used 0.994 (0.537–1.
Balloon slippage 0.836 (0.396–1.
Additional stent implantation 0.477 (0.141–1.ABG  coronary artery bypass graft surgery; CI  confidence interval; LAD  left anterhe hyperplastic tissue has a smooth slippery surface; with a
utting balloon, this problem is prevented by the blades,
hich anchor the balloon to the plaque during balloon
nflation, reducing the risk of dissection at the stent mar-
ins. This fact could be important when contemplating
dditional brachytherapy, a setting where there is the need
o carefully control the boundaries of the injured segment.
n the present trial, the CBA procedure was accompanied
y a significantly lower incidence of balloon slippage.
hy did CBA fail to improve the outcome? There are
ome possible explanations for this unexpected outcome.
irst, there is the relatively lower risk of ISR recurrence in
he two cohorts, which mostly had lesions shorter than 20
m and prevalently focal and multifocal lesions. In fact, the
ecurrence of restenosis after repeat angioplasty for the
reatment of ISR is influenced by its pattern (3–6,8,22),
ith a better outcome for focal than for diffuse ISR lesions,
nd a prohibitive recurrence rate for total occlusions (1). It
an be also speculated that the operators did not perform an
ppropriate number of cutting balloon inflations. This
ypothesis is supported by the observation of a similar mean
umber of balloon inflations in the two arms, but given the
onger length of the conventional PTCA balloons used,
here should have been a higher number inflations with the
horter cutting balloons to cover the same lesion length.
tudy limitations. A limitation of the present study is the
ack of data on IVUS assessment of the treated lesions, so as
o better understand the differential mechanisms of CBA
ersus conventional PTCA in ISR. A downside of the
utting balloon is that it is more costly than standard
Analysis Multivariate Analysis
p Value OR (95% CI) p Value
0.9513
0.6021
0.4308
0.0815 0.585 (0.307–1.110) 0.1041
0.5788
0.0941 0.350 (0.152–0.805) 0.0148
0.1368 1.030 (0.996–1.070) 0.0832
0.7323
0.0017 0.940 (0.904–0.978) 0.0028
0.1342
0.9209
0.3102
0.5829
0.0617
0.0058 0.417 (0.217–0.799) 0.0094
0.7916
0.4987
0.9857
0.6372
0.2369e
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620)ior descending coronary artery; MLD  minimal lumen diameter; OR  odds ratio.
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March 17, 2004:943–9 Cutting Balloon Versus PTCA for ISRalloons. A cost-benefit analysis was not performed in this
rial. Therefore, the issue of whether the increased expense
er procedure could be offset by the fewer stents used could
ot be solved. Only 82% of study groups had seven-month
ngiographic follow-up. However, as assumed for RES-
UT sample size calculation, about 20% of patients are
outinely lost to follow-up.
ONCLUSIONS AND FUTURE DIRECTIONS
he results of this study indicate that CBA and traditional
TCA are equally effective in preventing the recurrence of
SR. There were no differences in QCA measurements,
ecurrence of binary restenosis, or clinical event rates at
even-month follow-up between the two treatments. How-
ver, CBA was associated with some advantages: the pro-
edure required fewer balloons and was accompanied by a
ower incidence of balloon slippage (containment of trauma,
specially useful when combining CBA with brachyther-
py). In the CBA group, there was also an almost signifi-
antly lower need for additional stent implantation.
The question of the long-term superiority of CBA over
onventional PTCA for the treatment of ISR will be also
ddressed by another ongoing randomized multicenter Jap-
nese study—the Restenosis Reduction by Cutting Balloon
valuation (REDUCE II).
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PPENDIX
or a list of the Steering Committee, Data and Safety
onitoring Board, Core Laboratories, and Participating
enters of the RESCUT trial, please see the March 17,
004, issue of JACC at www.cardiosource.com/jacc.html.
